SOLIGENIX, INC. (SNGX)
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçets Disease
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçets Disease
📈 **POSITIVE** • High confidence analysis (90%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business